

Unit:

Technology:

Diagnostics



xDx



BioNTech Diagnostics Decoding Cancer

The Platform

Early detection of potentially fatal diseases and the selection of suitable therapies are crucial for successful treatment. BioNTech Diagnostics has the mission to provide new and innovative products and services to diagnose and characterize those diseases

with the final goal of extending the lives of patients and improving their quality of life. We currently focus on the development of new diagnostics products and services in oncology given the high medical need for effective cancer treatment.

The Science

At BioNTech Diagnostics, we constantly extend our product and service portfolio by leveraging flexible technologies.

- NGS: Next Generation Sequencing
- qPCR: Quantitative Polymerase Chain Reaction
- IHC: Immunohistochemistry
- ELISA: Enzyme - Linked Immunosorbent Assay
- High-throughput Peptide Synthesis and Standards

Our Vision


... is to make truly personalized medicine broadly available and to develop products and services for the next generation of personalized diagnostics and therapies.

... is to shape the future of medical testing by offering the tools to define the best therapeutic option for each individual patient with our extensive product and service offerings including biomarker discovery as well as corresponding validation assays, patient stratification and companion diagnostics for clinical monitoring.

Our Products and Service Offerings

The CE/IVD-marked breast cancer stratification kit MammaTyper® and the CE/IVD-marked RNXtract® kit for the extraction of mRNA from FFPE samples belong to BioNTech Diagnostics completed and clinically validated products available for partnering. Several other IVD and RUO (Research Use

Only) tests include assays for various cancer indications and products for companion diagnostics. The first companion diagnostic product Claudetect™ 18.2 is an immunohistochemistry-based IVD and was developed in cooperation with Ganymed Pharmaceuticals AG in 2013.



Our service offerings include, among others, biomarker discovery and validation and have resulted in CE/IVD-marked companion diagnostic products.


- | | |
|--|---|
| <ul style="list-style-type: none"> • Sample Preparation Kits • Screening Assays • Stratification Assays | <ul style="list-style-type: none"> • Companion Diagnostics (CDx) • Clinical Monitoring Assays • Individualized Diagnostics for Personalized Medicine |
|--|---|

We have also developed assays for clinical monitoring of patients that are currently used in clinical studies for malignant melanoma, glioblastoma and breast cancer. Furthermore, we are market leader in peptide/epitope-based biomarker discovery and have significantly contributed to the human proteome mapping project published in Nature in 2014.

Partnering

BioNTech Diagnostics commercializes its products and technologies through licensing and distribution partnerships and engages actively in collaborations with external partners. We are

currently partnering with large and medium-sized entities in the pharmaceutical, in vitro diagnostics, academic and commercial sectors and continuously expand our partnering activities.



BioNTech Diagnostics is embedded in external and internal partnerships.

MammaTyper® and RNXtract® are registered trademarks of BioNTech Diagnostics GmbH in Germany and other countries.